Plasma MicroRNA Levels Following Resection of Metastatic Melanoma
- PMID: 28469417
- PMCID: PMC5345922
- DOI: 10.1177/1177932217694837
Plasma MicroRNA Levels Following Resection of Metastatic Melanoma
Abstract
Melanoma remains the leading cause of skin cancer-related deaths. Surgical resection and adjuvant therapies can result in disease-free intervals for stage III and stage IV disease; however, recurrence is common. Understanding microRNA (miR) dynamics following surgical resection of melanomas is critical to accurately interpret miR changes suggestive of melanoma recurrence. Plasma of 6 patients with stage III (n = 2) and stage IV (n = 4) melanoma was evaluated using the NanoString platform to determine pre- and postsurgical miR expression profiles, enabling analysis of more than 800 miRs simultaneously in 12 samples. Principal component analysis detected underlying patterns of miR expression between pre- vs postsurgical patients. Group A contained 3 of 4 patients with stage IV disease (pre- and postsurgical samples) and 2 patients with stage III disease (postsurgical samples only). The corresponding preoperative samples to both individuals with stage III disease were contained in group B along with 1 individual with stage IV disease (pre- and postsurgical samples). Group A was distinguished from group B by statistically significant analysis of variance changes in miR expression (P < <0001). This analysis revealed that group A vs group B had downregulation of let-7b-5p, miR-520f, miR-720, miR-4454, miR-21-5p, miR-22-3p, miR-151a-3p, miR-378e, and miR-1283 and upregulation of miR-126-3p, miR-223-3p, miR-451a, let-7a-5p, let-7g-5p, miR-15b-5p, miR-16-5p, miR-20a-5p, miR-20b-5p, miR-23a-3p, miR-26a-5p, miR-106a-5p, miR-17-5p, miR-130a-3p, miR-142-3p, miR-150-5p, miR-191-5p, miR-199a-3p, miR-199b-3p, and miR-1976. Changes in miR expression were not readily evident in individuals with distant metastatic disease (stage IV) as these individuals may have prolonged inflammatory responses. Thus, inflammatory-driven miRs coinciding with tumor-derived miRs can blunt anticipated changes in expression profiles following surgical resection.
Keywords: Melanoma; microRNA; principal component analysis; surgical resection.
Conflict of interest statement
DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures


Similar articles
-
Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma.J Surg Oncol. 2018 Sep;118(3):501-509. doi: 10.1002/jso.25163. Epub 2018 Aug 21. J Surg Oncol. 2018. PMID: 30132912 Free PMC article.
-
Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis.Front Mol Neurosci. 2018 Aug 28;11:288. doi: 10.3389/fnmol.2018.00288. eCollection 2018. Front Mol Neurosci. 2018. PMID: 30210287 Free PMC article.
-
Expression of microRNAs and their target genes in melanomas originating from gynecologic sites.PLoS One. 2023 Jun 29;18(6):e0285804. doi: 10.1371/journal.pone.0285804. eCollection 2023. PLoS One. 2023. PMID: 37384650 Free PMC article.
-
microRNAs Promoting Growth of Gastric Cancer Xenografts and Correlation to Clinical Prognosis.Cancer Genomics Proteomics. 2021 Jan-Feb;18(1):1-15. doi: 10.21873/cgp.20237. Epub 2021 Jan 8. Cancer Genomics Proteomics. 2021. PMID: 33419892 Free PMC article. Review.
-
MicroRNA networks in prolactinoma tumorigenesis: a scoping review.Cancer Cell Int. 2024 Dec 19;24(1):418. doi: 10.1186/s12935-024-03529-5. Cancer Cell Int. 2024. PMID: 39702128 Free PMC article.
Cited by
-
Assessment of Circulating miRNA-17 and miRNA-222 Expression Profiles as Non-Invasive Biomarkers in Egyptian Patients with Non-Small-Cell Lung Cancer.Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1927-1933. doi: 10.31557/APJCP.2019.20.6.1927. Asian Pac J Cancer Prev. 2019. PMID: 31244320 Free PMC article.
-
miR-21-5p promotes cell proliferation and G1/S transition in melanoma by targeting CDKN2C.FEBS Open Bio. 2020 May;10(5):752-760. doi: 10.1002/2211-5463.12819. Epub 2020 Mar 24. FEBS Open Bio. 2020. PMID: 32090490 Free PMC article.
-
Investigating the tumor-immune microenvironment through extracellular vesicles from frozen patient biopsies and 3D cultures.Front Immunol. 2023 May 25;14:1176175. doi: 10.3389/fimmu.2023.1176175. eCollection 2023. Front Immunol. 2023. PMID: 37304281 Free PMC article.
-
MicroRNA-451a prevents cutaneous squamous cell carcinoma progression via the 3-phosphoinositide-dependent protein kinase-1-mediated PI3K/AKT signaling pathway.Exp Ther Med. 2021 Feb;21(2):116. doi: 10.3892/etm.2020.9548. Epub 2020 Dec 3. Exp Ther Med. 2021. Retraction in: Exp Ther Med. 2024 May 13;28(1):280. doi: 10.3892/etm.2024.12568. PMID: 33335579 Free PMC article. Retracted.
-
MiR-23a-3p promoted G1/S cell cycle transition by targeting protocadherin17 in hepatocellular carcinoma.J Physiol Biochem. 2020 Feb;76(1):123-134. doi: 10.1007/s13105-020-00726-4. Epub 2020 Jan 28. J Physiol Biochem. 2020. PMID: 31994011
References
-
- Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–289. - PubMed
-
- Thalanayar PM, Agarwala SS, Tarhini AA. Melanoma adjuvant therapy. Chin Clin Oncol. 2014;3:26. - PubMed
-
- Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–530. - PubMed
-
- Sullivan R, LoRusso P, Boerner S, Dummer R. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015;35:177–186. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources